Dyne Therapeutics Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the transition period from ________________ to ________________Commission File Number: 001-39509 Dyne Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware(State or other jurisdiction ofincorporation or organization)1560 Trapelo RoadWaltham, Massachusetts(Address of principal executive offices) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common Stock, $0.0001 par value per share Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Table of Contents PageCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS2PART I.FINANCIAL INFORMATION5Item 1.Financial Statements (Unaudited)5Condensed Consolidated Balance Sheets5Condensed Consolidated Statements of Operations and Comprehensive Loss6Condensed Consolidated Statements of Stockholders’ Equity7Condensed Consolidated Statements of Cash Flows8Notes to Unaudited Condensed Consolidated Financial Statements9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures29PART II.OTHER INFORMATION29Item 1.Legal Proceedings29Item 1A.Risk Factors29Item 2.Unregistered Sales of Equity Securities and Use of Proceeds94Item 3.Defaults Upon Senior Securities94Item 4.Mine Safety Disclosures94Item 5.Other Information94Item 6.Exhibits95Signatures96 We own or have rights to trademarks, service marks and trade names that we use in connection with the operation ofour business, including our corporate name, logos and website names. The service marks and trademarks that we owninclude the marks Dyne Therapeutics®and FORCE™. Other trademarks, service marks and trade names appearing inthis Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, some of thetrademarks, service marks and trade names referred to in this Quarterly Report on Form 10-Q are listed without the ®and ™ symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, servicemarks and trade names. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or this Quarterly Report, contains forward-looking statements within the meaningof the U.S. Private Securities Litigation Reform Act and Section 21E of the Securities Exchange Act of 1934, asamended, that involve substantial risk and uncertainties. All statements other than statements of historical fact,contained in this Quarterly Report, including statements regarding our strategy, future operations, future financialposition, future revenue, projected costs, prospects, plans and objectives of management, are forward-lookingstatements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”“potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these words or other similarexpressions are intended to identify forward-looking statements, although not all forward-looking statements containthese identifying words. The forward-looking statements in this Quarterly Report include, among other things, statements about: •the initiation, timing, design, progress and results of our research and